台灣臨床試驗主持人資料庫|TPIDB

2017-06-28 - 2020-12-31

Phase I

A Phase I safety and tolerability study of T-1101 (Tosylate) as a powder for constitution (OPC) in patients with advanced refractory solid tumors

Condition/Disease

Advanced Refractory Solid Tumors
Test Drug

T-1101 (Tosylate)

Participate Sites
5Sites

Suspended4Sites

白禮源

China Medical University Hospital-Taipei

未分科

趙祖怡

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Hematology & Oncology

2017-10-01 - 2021-03-31

Phase II

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of CS02 Tablet in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone

Condition/Disease

Type 2 Diabetes Mellitus
Test Drug

CS02 Tablet

Participate Sites
13Sites

Recruiting2Sites

Terminated10Sites

陳清助

China Medical University Hospital-Taipei

未分科

陳涵栩

Taipei Veterans General Hospital

Division of Endocrinology

2015-10-26 - 2017-05-30

Phase III

A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus Genotype 1 Infection (ENDURANCE-1)

Condition/Disease

Chronic Hepatitis C Virus Genotype 1 Infection
Test Drug

ABT-493/ABT-530

Participate Sites
9Sites

Terminated8Sites

彭成元

China Medical University Hospital-Taipei

未分科

朱啟仁

Taipei Veterans General Hospital

Digestive System Department

2016-10-10 - 2022-08-31

Phase III

A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of ABT-494 for induction and maintenance therapy in subjects with moderately to severely active ulcerative colitis.

Condition/Disease

Ulcerative colitis
Test Drug

Upadacitinib(ABT-494)

Participate Sites
8Sites

Terminated6Sites

周仁偉

China Medical University Hospital-Taipei

未分科

林春吉

Taipei Veterans General Hospital

Division of Colorectal Surgery

2017-12-01 - 2020-04-01

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

Condition/Disease

Crohn’s Disease
Test Drug

Risankizumab(ABBV-066)

Participate Sites
6Sites

Terminated5Sites

周仁偉

China Medical University Hospital-Taipei

未分科

2016-06-06 - 2022-03-10

Phase III

A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs

Condition/Disease

Rheumatoid Arthritis
Test Drug

ABT-494

Participate Sites
8Sites

Terminated7Sites

黃春明

China Medical University Hospital-Taipei

未分科

2017-04-01 - 2018-12-31

Phase III

A Single Arm, Open-label Study to Evaluatehe Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naive Adults with Chronic Hepatitis C Virus (HCV) Genotype 1, 2,4, 5 or 6Infection and Compensated Cirrhosis

Condition/Disease

Chronic Hepatitis C Virus (HCV)
Test Drug

Glecaprevir、Pibrentasvir

Participate Sites
4Sites

Terminated3Sites

彭成元

China Medical University Hospital-Taipei

未分科

朱啟仁

Taipei Veterans General Hospital

Digestive System Department

2018-11-01 - 2021-03-30

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Ulcerative Colitis

Condition/Disease

Moderately to Severely Active Ulcerative Colitis
Test Drug

Upadacitinib (ABT-494)

Participate Sites
6Sites

Recruiting2Sites

Terminated2Sites

周仁偉

China Medical University Hospital-Taipei

未分科

林春吉

Taipei Veterans General Hospital

Division of Colorectal Surgery

2018-08-31 - 2020-12-31

Phase II

Efficacy and safety of 3 doses of S201086/GLPG1972 administered orally once daily in patients with kneeosteoarthritis. A 52-week international, multi-regional, multicenter,randomized, double-blind, placebo-controlled, doseranging study.

Condition/Disease

kneeosteoarthritis
Test Drug

S201086/GLPG1972

Participate Sites
4Sites

Terminated3Sites

黃春明

China Medical University Hospital-Taipei

未分科

2018-11-01 - 2021-12-31

Phase III

A Randomized, Controlled, Double-blind Continuation Study Comparing the Long-term Safety and Efficacy of Orelvo (voclosporin) (23.7 mg Twice Daily) with Placebo in Subjects with Lupus Nephritis

Condition/Disease

Lupus Nephritis
Test Drug

Orelvo (voclosporin)

Participate Sites
4Sites

Terminated2Sites

藍忠亮

China Medical University Hospital-Taipei

未分科

藍忠亮

China Medical University Hospital

Division of Rheumatology

Search Result

List